Metformina + Sitagliptina Anova

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Metformina + Sitagliptina Anova (Metformin Hydrochloride, Sitagliptin)

Q: What is Metformina + Sitagliptina Anova used for?

Metformina + Sitagliptina Anova is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, particularly when diet, exercise, or single‑agent therapy have not achieved target glycaemic levels.

Q: How does the combination of metformin and sitagliptin work?

Metformin lowers hepatic glucose production and enhances insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, increasing incretin hormones that stimulate insulin release and suppress glucagon. Together they address fasting and post‑prandial glucose elevations.

Q: What is the usual dose of Metformina + Sitagliptina Anova?

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant medications.

Q: Is Metformina + Sitagliptina Anova safe during pregnancy or breastfeeding?

Use during pregnancy or lactation should only occur if the potential benefit outweighs any possible risk to the fetus or infant. The prescriber must evaluate the clinical situation and discuss safety considerations with the patient.

Q: How do I order Metformina + Sitagliptina Anova from GNH India?

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does this combination compare with other antidiabetic options?

Compared with metformin alone, the addition of sitagliptin offers greater post‑prandial glucose reduction without the weight gain associated with some sulfonylureas. Unlike insulin, it is administered orally and carries a lower risk of severe hypoglycaemia when used as monotherapy.

Q: What are the storage and handling requirements for this product?

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Q: How is Metformina + Sitagliptina Anova administered?

The medication is taken orally, usually with meals to minimise gastrointestinal discomfort. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with this therapy?

The most critical adverse events include lactic acidosis (particularly in patients with renal impairment), severe hypoglycaemia when combined with insulin secretagogues, and acute pancreatitis. Prompt medical attention is required if any of these symptoms arise.

Q: Who should not use Metformina + Sitagliptina Anova?

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. The prescriber should also assess contraindications in hepatic disease and pregnancy.

Metformin hydrochloride and sitagliptin, the active ingredient in Metformina + Sitagliptina Anova, is a biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy are insufficient.

GNH India supplies Metformina + Sitagliptina Anova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratórios Anova - Produtos Farmacêuticos, Lda

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformina + Sitagliptina Anova is used in the treatment of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms.

Type 2 diabetes mellitus: improves overall glycaemic control when combined with diet and exercise.
Inadequate control on metformin alone: provides additional glucose‑lowering effect as part of combination therapy.
Adults requiring dual therapy: offers a single‑pill option to simplify regimens and enhance adherence.

How It Works

Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to higher endogenous incretin levels that enhance glucose‑dependent insulin secretion and suppress glucagon release. The combined actions result in lower fasting and post‑prandial blood glucose concentrations.

Side Effects

The following adverse reactions have been reported with the metformin/sitagliptin combination.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
Headache: mild to moderate intensity.
Mild hypoglycaemia: especially when used with insulin secretagogues.
Upper respiratory tract infection: transient symptoms.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening metabolic complication.
Severe hypoglycaemia: can occur with concomitant sulfonylureas or insulin.
Pancreatitis: acute inflammation of the pancreas requiring urgent care.
Allergic reactions: rash, angio‑edema, or anaphylaxis.
Hepatic dysfunction: elevated liver enzymes or hepatitis.
Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²).
Hepatic function monitoring: use with caution in patients with liver disease.
Lactic acidosis risk: discontinue promptly if symptoms of metabolic acidosis develop.
Pregnancy and lactation: only if the potential benefit justifies the potential risk to the fetus or infant.
Drug interaction review: evaluate concomitant medications that may affect glucose levels or renal clearance.
Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Metformina + Sitagliptina Anova may interact with several drug classes.

Major Interactions (Avoid)

Cimetidine: can increase metformin plasma concentrations.
Iodinated contrast agents: risk of acute kidney injury, may precipitate lactic acidosis.
Insulin secretagogues (e.g., sulfonylureas): heightened risk of severe hypoglycaemia.
Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin levels.
Alcohol excess: potentiates metformin‑associated lactic acidosis.

Moderate Interactions (Monitor Closely)

Diuretics (thiazides): may affect renal clearance of metformin.
ACE inhibitors/ARBs: monitor renal function and electrolytes.
Beta‑blockers: can mask hypoglycaemia symptoms.
Warfarin: occasional alterations in INR, require monitoring.

Frequently Asked Questions

Metformina + Sitagliptina Anova is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, particularly when diet, exercise, or single‑agent therapy have not achieved target glycaemic levels.

Metformin lowers hepatic glucose production and enhances insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, increasing incretin hormones that stimulate insulin release and suppress glucagon. Together they address fasting and post‑prandial glucose elevations.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant medications.

Use during pregnancy or lactation should only occur if the potential benefit outweighs any possible risk to the fetus or infant. The prescriber must evaluate the clinical situation and discuss safety considerations with the patient.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, the addition of sitagliptin offers greater post‑prandial glucose reduction without the weight gain associated with some sulfonylureas. Unlike insulin, it is administered orally and carries a lower risk of severe hypoglycaemia when used as monotherapy.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually with meals to minimise gastrointestinal discomfort. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

The most critical adverse events include lactic acidosis (particularly in patients with renal impairment), severe hypoglycaemia when combined with insulin secretagogues, and acute pancreatitis. Prompt medical attention is required if any of these symptoms arise.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. The prescriber should also assess contraindications in hepatic disease and pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 06 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.